TRACON Pharmaceuticals Announces Publication Of Phase 2 Clinical Data For TRC102 In Patients With Glioblastoma In Clinical Cancer Research; Study Highlights Activity Of TRC102 Combined With Temodar Chemotherapy In Recurrent Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
TRACON Pharmaceuticals announced the publication of Phase 2 clinical data for TRC102 in patients with glioblastoma. The study highlights the activity of TRC102 combined with Temodar chemotherapy in recurrent glioblastoma, showing extended survival in patients with activation of DNA damage response pathways.
June 11, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TRACON Pharmaceuticals published positive Phase 2 clinical data for TRC102 in glioblastoma patients, showing extended survival with the TRC102 and Temodar combination. This could boost investor confidence and positively impact the stock price in the short term.
The publication of positive clinical data is a significant milestone for TRACON Pharmaceuticals. The demonstrated extended survival in patients could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100